Press Releases

Press Releases

Date Title
5/4/20 Vir and Alnylam Identify RNAi Therapeutic Development Candidate, VIR-2703 (ALN-COV), Targeting SARS-CoV-2 for the Treatment of COVID-19
4/28/20 Vir Biotechnology to Provide Corporate Update and Report First Quarter 2020 Financial Results on May 12, 2020
4/15/20 VIR-2218 Demonstrates Dose-Dependent and Durable Reductions of Hepatitis B Surface Antigen in Phase 1/2 Trial
4/9/20 Samsung Biologics and Vir Biotechnology Enter into Agreement for Large Scale Manufacture of SARS-COV-2 Antibodies for Potential COVID-19 Treatment
4/8/20 Vir Biotechnology to Host Key Opinion Leader Call and Present Update on Phase 1/2 HBV Clinical Trial with siRNA VIR-2218
4/6/20 GSK and Vir Biotechnology enter collaboration to find coronavirus solutions
4/2/20 Vir and Alnylam Expand Collaboration to Advance Investigational RNAi Therapeutics Targeting Host Factors for the Treatment of COVID-19
3/30/20 Generation Bio and Vir Biotechnology to Collaborate on Research to Leverage Scalable Non-Viral Gene Therapy Platform for Durable Production of Monoclonal Antibodies Against Coronavirus That Causes COVID-19
3/26/20 Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2019 Financial Results
3/25/20 Vir Biotechnology Proceeding with Two Clinical Development Candidates for COVID-19
Displaying 11 - 20 of 30